Published in Cancer on December 02, 2013
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology (2016) 0.78
Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol (2016) 0.77
Role of surgical resection for non-colorectal non-neuroendocrine liver metastases. World J Hepatol (2017) 0.75
Delayed presentation of a metastatic choroidal melanoma to the liver: The latency of an elective metastatic localization. Int J Surg Case Rep (2015) 0.75
Making the Case: Intra-arterial Therapy for Less Common Metastases. Semin Intervent Radiol (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol (2005) 2.41
TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist (2006) 2.17
Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol (2008) 2.11
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol (2013) 2.08
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol (2012) 1.93
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release (2013) 1.66
Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol (2011) 1.63
20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol (2011) 1.60
Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol (2008) 1.55
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol (2004) 1.51
Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol (2011) 1.48
Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann Surg Oncol (2010) 1.44
Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics (2008) 1.44
Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol (2010) 1.42
Proper margins of excision in dermatofibrosarcoma protuberans: wide or narrow? Ann Surg Oncol (2008) 1.42
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2005) 1.36
Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol (2010) 1.35
Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J (2004) 1.24
Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer (2013) 1.23
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 1.23
Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg (2002) 1.22
Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay. J Cell Biochem (2006) 1.20
Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release (2010) 1.19
Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology (2007) 1.18
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun (2013) 1.17
Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control (2009) 1.15
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer (2009) 1.15
Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer (2009) 1.15
Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol (2012) 1.11
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst (2009) 1.11
Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res (2007) 1.11
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol (2010) 1.11
The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol (2003) 1.10
Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol (2013) 1.09
Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res (2010) 1.08
Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol (2011) 1.07
Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys (2002) 1.07
Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol (2007) 1.07
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer (2010) 1.06
Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J Control Release (2013) 1.05
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol (2003) 1.04
Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery (2002) 1.04
Epidemiological evidence that UVA radiation is involved in the genesis of cutaneous melanoma. Curr Opin Oncol (2011) 1.04
Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol (2011) 1.03
Treatment options for limited or symptomatic metastatic melanoma. Cancer Control (2008) 1.03
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol (2009) 1.03
Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer (2006) 1.03
Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer (2005) 1.03
Current diagnosis and management of retroperitoneal sarcoma. Cancer Control (2011) 1.03
Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol (2009) 1.01
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer (2013) 1.01
The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol (2010) 1.01
Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol (2011) 1.01
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol (2010) 1.00
Immunologic functions as prognostic indicators in melanoma. Mol Oncol (2011) 1.00
Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Colon Rectum (2005) 0.99
Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control (2009) 0.99
Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol (2013) 0.98
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother (2003) 0.98
Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. J Surg Oncol (2011) 0.98
Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified. J Clin Oncol (2009) 0.98
The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum (2009) 0.97
Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol (2012) 0.97
Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother (2010) 0.97
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer (2009) 0.97
Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol (2011) 0.96
Lymphatic mapping and sentinel node biopsy: a surgical perspective. Semin Nucl Med (2005) 0.96
Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? Ann Surg Oncol (2013) 0.96
Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol (2013) 0.96
Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration. Angiogenesis (2013) 0.95
One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg (2004) 0.95
Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden. Ann Surg Oncol (2010) 0.95
Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol (2005) 0.94
Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Oncologist (2009) 0.94
Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol (2007) 0.93
Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol (2009) 0.93
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs (2008) 0.92
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol (2013) 0.92
Value of intraoperative radiotherapy in locally advanced rectal cancer. Dis Colon Rectum (2006) 0.92
Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol (2006) 0.92
The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol (2012) 0.91